Diffuse large B-cell lymphoma associated with the use of biologic and other investigational agents: The importance of long-term post-marketing safety surveillance

Allison Goddard, Judy H. Borovicka, Dennis P. West, Andrew M. Evens, Anne Laumann*

*Corresponding author for this work

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

This case report describes a patient who developed diffuse large B-cell lymphoma (DLBCL) after receiving courses of two investigational biologic agents and cyclosporine followed by more than four years of subcutaneous efalizumab for the treatment of extensive chronic plaque psoriasis. Three years later, the patient remains free of lymphoma and his psoriasis is well controlled with thrice-weekly narrow-band ultraviolet phototherapy. This case emphasizes the importance of continued long-term post-marketing safety surveillance and the early reporting of all possible serious side effects, including cancers, related to the use of any newly available product. In particular, surveillance should focus on the immunomodulating biologic agents in order to identify possible dangerous sequelae.

Original languageEnglish (US)
Pages (from-to)80-83
Number of pages4
JournalJournal of Drugs in Dermatology
Volume10
Issue number1
StatePublished - Jan 1 2011

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Diffuse large B-cell lymphoma associated with the use of biologic and other investigational agents: The importance of long-term post-marketing safety surveillance'. Together they form a unique fingerprint.

  • Cite this